Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
As of close of business last night, ATAI Life Sciences N.V.’s stock clocked out at $1.97, up 2.07% from its previous closing price of $1.93. In other words, the price has increased by $2.07 from its previous closing price. On the day, 1.15 million shares were traded. ATAI stock price reached its highest trading level at $2.05 during the session, while it also had its lowest trading level at $1.88.
Ratios:
To gain a deeper understanding of ATAI’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 9.22 and its Current Ratio is at 9.22. In the meantime, Its Debt-to-Equity ratio is 0.07 whereas as Long-Term Debt/Eq ratio is at 0.07.
On November 01, 2022, Loop Capital started tracking the stock assigning a Buy rating and target price of $18.
On November 30, 2021, Maxim Group started tracking the stock assigning a Buy rating and target price of $25.Maxim Group initiated its Buy rating on November 30, 2021, with a $25 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Apr 02 ’24 when Rao Srinivas sold 61,640 shares for $1.85 per share. The transaction valued at 114,034 led to the insider holds 113,360 shares of the business.
Kirpekar Sahil sold 35,801 shares of ATAI for $66,232 on Apr 02 ’24. The Chief Business Officer now owns 64,199 shares after completing the transaction at $1.85 per share. On Apr 02 ’24, another insider, Johnson Anne Nagengast, who serves as the Chief Financial Officer of the company, sold 27,410 shares for $1.85 each. As a result, the insider received 50,708 and left with 73,590 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ATAI now has a Market Capitalization of 329803584 and an Enterprise Value of 170711008. For the stock, the TTM Price-to-Sale (P/S) ratio is 1063.86 while its Price-to-Book (P/B) ratio in mrq is 1.35. Its current Enterprise Value per Revenue stands at 543.666 whereas that against EBITDA is -1.4.
Stock Price History:
The Beta on a monthly basis for ATAI is 0.95, which has changed by 0.042328 over the last 52 weeks, in comparison to a change of 0.24191546 over the same period for the S&P500. Over the past 52 weeks, ATAI has reached a high of $2.85, while it has fallen to a 52-week low of $1.02. The 50-Day Moving Average of the stock is -0.42%, while the 200-Day Moving Average is calculated to be 20.45%.
Shares Statistics:
It appears that ATAI traded 1.62M shares on average per day over the past three months and 1058190 shares per day over the past ten days. A total of 166.03M shares are outstanding, with a floating share count of 116.45M. Insiders hold about 30.44% of the company’s shares, while institutions hold 8.24% stake in the company. Shares short for ATAI as of 1713139200 were 5901316 with a Short Ratio of 3.65, compared to 1710460800 on 5205386. Therefore, it implies a Short% of Shares Outstanding of 5901316 and a Short% of Float of 4.62.
Earnings Estimates
Investors are eagerly awaiting the insights provided by 5.0 analysts currently analyzing and rating the stock of ATAI Life Sciences N.V. (ATAI).On average, analysts expect EPS of -$0.18 for the current quarter, with a high estimate of -$0.14 and a low estimate of -$0.22, while EPS last year was -$0.21. The consensus estimate for the next quarter is -$0.2, with high estimates of -$0.14 and low estimates of -$0.24.
Analysts are recommending an EPS of between -$0.59 and -$0.93 for the fiscal current year, implying an average EPS of -$0.77. EPS for the following year is -$0.77, with 6.0 analysts recommending between -$0.54 and -$1.01.
